Imaging Tracer Tested During Lung Bronchoscopy in People With Suspected Lung Cancer
Tests a glowing imaging dye during bronchoscopy in adults with suspicious lung spots.
Plain-language title generated from the registry record
Registry title: Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy
Key facts
- Where
- Groningen, NetherlandsSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a lung nodule, with or without enlarged lymph nodes, that is thought to be cancer and who need a bronchoscopy to take tumor samples.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- At least one lung nodule, with or without abnormal lymph nodes, that is considered malignant. The nodule can be inside the airway, near the airway or at the edge of the lung.
- Earlier treatment
- No earlier infusion reactions to bevacizumab.
Main reasons for not taking part
- Earlier infusion reactions to bevacizumab
- Medical or mental health conditions that stop the person from giving informed consent
- Pregnancy or breast feeding
Read by machine on 12 November 2026.
Where in Netherlands
- Universitair Medisch Centrum GroningenGroningen, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Medical Center Groningen
- Trial code
- NCT06809946EU 2024-510793-24-00
- Record updated
- 30 March 2026
- Original description
In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and/or lymph nodes considered to be malignant.Read full original descriptionShow less
Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy in Patients With a Pulmonary Lesion Considered to be Malignant - DEFLECT I
In this feasibility study, bronchoscopy will be combined with fluorescence molecular imaging using the near-infrared fluorescence (NIRF) tracer bevacizumab-800CW for assessment of pulmonary lesions and/or lymph nodes considered to be malignant.
Inclusion: Signed informed consent prior to participation in the study; Age ≥ 18 years; Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule - with or without pathological lymph nodes - which is considered malignant (independent of its primary origin); Patient is considered fit to undergo a diagnostic and/or therapeutic bronchoscopy (with or without addition of virtual navigation and/or endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.
Exclusion: History of infusion reactions to bevacizumab; Medical or psychiatric conditions that compromise the patient's ability to give informed consent; Pregnancy or breast feeding.